Literature DB >> 24292367

Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis.

Yuag-Meng Liu1, Yu-Jen Cheng, Yu-Lin Li, Chun-Eng Liu, Wu-Huei Hsu.   

Abstract

BACKGROUND: Whether antituberculosis (anti-TB) treatment in patients with chronic viral hepatitis affects the incidence and onset time of drug-induced hepatotoxicity (DIH) is still controversial. The aim of this retrospective study was to find out whether chronic viral hepatitis affects the incidence and onset time of DIH.
METHODS: All patients diagnosed with active TB and being treated at a tertiary referral hospital between 2002 and 2009 were identified from medical records, from which 553 patients were enrolled in the study. The incidence and onset of DIH in patients with and without chronic viral hepatitis (controls) were compared.
RESULTS: The incidence of DIH was similar in patients with and without chronic hepatitis (8 % [32/392] vs. 7 % [11/161], P > 0.05). The incidence of transient liver function impairment (TLI) was significantly lower in controls than in chronic hepatitis patients (2 % [9/392] vs. 12 % [20/161], P < 0.001. The mean onset times of DIH in the control, hepatitis B virus (HBV), and hepatitis C virus (HCV) groups were not significantly different (40, 39, and 67 days, respectively, all P > 0.05). The mean onset times of TLI in the control, HBV, and HCV groups were significantly different (23, 48, and 68 days, respectively, all P < 0.05).
CONCLUSIONS: Liver function impairment during anti-TB therapy in patients with chronic viral hepatitis was due to mostly TLI, with TLI occurring later than in controls. Chronic viral hepatitis had no significant effect on the incidence of DIH.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24292367     DOI: 10.1007/s00408-013-9535-8

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  30 in total

1.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

2.  Fatal hepatotoxicity of anti-tubercular chemotherapy.

Authors:  R M Whittington
Journal:  Lancet       Date:  1991-10-26       Impact factor: 79.321

3.  Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load.

Authors:  Jann-Yuan Wang; Chen-Hua Liu; Fu-Chang Hu; Hsiu-Ching Chang; Jia-Luen Liu; Jong-Min Chen; Chong-Jen Yu; Li-Na Lee; Jia-Horng Kao; Pan-Chyr Yang
Journal:  J Infect       Date:  2011-04-28       Impact factor: 6.072

4.  Antituberculosis drug-induced hepatitis and HBsAg carriers.

Authors:  D N Amarapurkar; P P Prabhudesai; R H Kalro; H G Desai
Journal:  Tuber Lung Dis       Date:  1993-06

5.  Adverse effects of antituberculosis drugs.

Authors:  D J Girling
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

6.  Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

Authors:  J N Pande; S P Singh; G C Khilnani; S Khilnani; R K Tandon
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

7.  Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.

Authors:  Byoung Hoon Lee; Won-Jung Koh; Moon Seok Choi; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O Jung Kwon
Journal:  Chest       Date:  2005-04       Impact factor: 9.410

8.  Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.

Authors:  Ramesh Kumar; Vikram Bhatia; Shankar Khanal; V Sreenivas; S Datta Gupta; Subrat K Panda; Subrat K Acharya
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

9.  Seroprevalence of antibody to hepatitis E virus among Chinese subjects in Taiwan.

Authors:  S D Lee; Y J Wang; R H Lu; C Y Chan; K J Lo; R Moeckli
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

10.  Assessing trends and predictors of tuberculosis in Taiwan.

Authors:  Chung-Min Liao; Nan-Hung Hsieh; Tang-Luen Huang; Yi-Hsien Cheng; Yi-Jun Lin; Chia-Pin Chio; Szu-Chieh Chen; Min-Pei Ling
Journal:  BMC Public Health       Date:  2012-01-12       Impact factor: 3.295

View more
  5 in total

Review 1.  Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury.

Authors:  Aida Ortega-Alonso; Camilla Stephens; M Isabel Lucena; Raúl J Andrade
Journal:  Int J Mol Sci       Date:  2016-05-12       Impact factor: 5.923

2.  The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.

Authors:  Huang-Shen Lin; Chun-Wen Cheng; Ming-Shyan Lin; Yen-Li Chou; Pey-Jium Chang; Jing-Chi Lin; Jung-Jr Ye
Journal:  Clin Interv Aging       Date:  2016-03-11       Impact factor: 4.458

3.  Early monitoring for detection of antituberculous drug-induced hepatotoxicity.

Authors:  Chang Min Lee; Sang Soo Lee; Jeong Mi Lee; Hyun Chin Cho; Wan Soo Kim; Hong Jun Kim; Chang Yoon Ha; Hyun Jin Kim; Tae Hyo Kim; Woon Tae Jung; Ok Jae Lee
Journal:  Korean J Intern Med       Date:  2015-12-28       Impact factor: 2.884

4.  Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury.

Authors:  Wan Soo Kim; Sang Soo Lee; Chang Min Lee; Hong Jun Kim; Chang Yoon Ha; Hyun Jin Kim; Tae Hyo Kim; Woon Tae Jung; Ok Jae Lee; Jeong Woo Hong; Hyun Seon You; Hyun Chin Cho
Journal:  BMC Infect Dis       Date:  2016-02-01       Impact factor: 3.090

5.  Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST.

Authors:  Eliana Abreu Santos; José Carlos Saraiva Gonçalves; Marcos K Fleury; Afrânio L Kritski; Martha M Oliveira; Luciane S Velasque; José Roberto Lapa E Silva; Rita de Cássia E Estrela
Journal:  Braz J Infect Dis       Date:  2019-11-04       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.